The Multifaceted Functionality of Plasmacytoid Dendritic Cells in Gastrointestinal Cancers: A Potential Therapeutic Target?

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Jun 27

PMID 38927922

Authors

Frederik J Hansen

Paul David

Georg F Weber

Affiliations

Soon will be listed here.

Abstract

Gastrointestinal (GI) tumors pose a significant global health burden, necessitating the exploration of novel therapeutic approaches. Plasmacytoid dendritic cells (pDCs) play a crucial role in tumor immunity, exhibiting both anti-tumor and pro-tumor effects. This review aims to summarize the role of pDCs in different types of GI tumors and assess their potential as therapeutic targets. In gastric cancer, hepatocellular carcinoma, and intrahepatic cholangiocarcinoma, increased infiltration of pDCs was associated with a worse outcome, whereas in esophageal cancer, pancreatic cancer, and colorectal cancer, pDC infiltration improved the outcome. Initial animal studies of gastric cancer and hepatocellular carcinoma showed that pDCs could be a successful therapeutic target. In conclusion, pDCs play a multifaceted role in GI tumors, influencing both anti-tumor immunity and tumor progression. Further research is needed to optimize their clinical application and explore combinatorial approaches.

Citing Articles

Uncovering key genes and molecular mechanisms of dendritic cell dysfunction in Esophageal Cancer: implications for Novel Diagnostic and therapeutic strategies.

Li Y, Zeng J, Yu C, Shen W, Xi Y Discov Oncol. 2024; 15(1):790.

PMID: 39692816 PMC: 11655908. DOI: 10.1007/s12672-024-01620-x.

References

Villani A, Satija R, Reynolds G, Sarkizova S, Shekhar K, Fletcher J . Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science. 2017; 356(6335). PMC: 5775029. DOI: 10.1126/science.aah4573. View

Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z . CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008; 322(5899):271-5. DOI: 10.1126/science.1160062. View

Balan S, Saxena M, Bhardwaj N . Dendritic cell subsets and locations. Int Rev Cell Mol Biol. 2019; 348:1-68. DOI: 10.1016/bs.ircmb.2019.07.004. View

Sozzani S, Vermi W, Del Prete A, Facchetti F . Trafficking properties of plasmacytoid dendritic cells in health and disease. Trends Immunol. 2010; 31(7):270-7. DOI: 10.1016/j.it.2010.05.004. View

Kumar S, Fajardo J, Birge R, Sriram G . Crk at the quarter century mark: perspectives in signaling and cancer. J Cell Biochem. 2013; 115(5):819-25. DOI: 10.1002/jcb.24749. View

Wculek S, Cueto F, Mujal A, Melero I, Krummel M, Sancho D . Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2019; 20(1):7-24. DOI: 10.1038/s41577-019-0210-z. View

Lippens C, Duraes F, Dubrot J, Brighouse D, Lacroix M, Irla M . IDO-orchestrated crosstalk between pDCs and Tregs inhibits autoimmunity. J Autoimmun. 2016; 75():39-49. PMC: 5127883. DOI: 10.1016/j.jaut.2016.07.004. View

Davila R, Davila M . Recent Advancements in the Diagnosis and Treatment of Gastrointestinal Cancers. Gastroenterol Clin North Am. 2022; 51(3):xiii-xiv. DOI: 10.1016/j.gtc.2022.07.009. View

Suszczyk D, Skiba W, Zardzewialy W, Pawlowska A, Wlodarczyk K, Polak G . Clinical Value of the PD-1/PD-L1/PD-L2 Pathway in Patients Suffering from Endometriosis. Int J Mol Sci. 2022; 23(19). PMC: 9570092. DOI: 10.3390/ijms231911607. View

10.

Cheng Y, Lemke-Miltner C, Wongpattaraworakul W, Wang Z, Chan C, Salem A . immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy. J Immunother Cancer. 2020; 8(2). PMC: 7566437. DOI: 10.1136/jitc-2020-000940. View

11.

Khalaf N, El-Serag H, Abrams H, Thrift A . Burden of Pancreatic Cancer: From Epidemiology to Practice. Clin Gastroenterol Hepatol. 2020; 19(5):876-884. PMC: 8559554. DOI: 10.1016/j.cgh.2020.02.054. View

12.

Matsui T, Connolly J, Michnevitz M, Chaussabel D, Yu C, Glaser C . CD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions. J Immunol. 2009; 182(11):6815-23. PMC: 2749454. DOI: 10.4049/jimmunol.0802008. View

13.

Snell L, McGaha T, Brooks D . Type I Interferon in Chronic Virus Infection and Cancer. Trends Immunol. 2017; 38(8):542-557. PMC: 8059441. DOI: 10.1016/j.it.2017.05.005. View

14.

Stary G, Bangert C, Tauber M, Strohal R, Kopp T, Stingl G . Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med. 2007; 204(6):1441-51. PMC: 2118597. DOI: 10.1084/jem.20070021. View

15.

Wang X, Liu Y, Diao Y, Gao N, Wan Y, Zhong J . Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil. J Transl Med. 2018; 16(1):120. PMC: 5941430. DOI: 10.1186/s12967-018-1501-z. View

16.

Fu C, Zhou L, Mi Q, Jiang A . Plasmacytoid Dendritic Cells and Cancer Immunotherapy. Cells. 2022; 11(2). PMC: 8773673. DOI: 10.3390/cells11020222. View

17.

Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D . Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2008; 27(2):186-92. DOI: 10.1200/JCO.2008.18.7229. View

18.

Moreno Ayala M, Campbell T, Zhang C, Dahan N, Bockman A, Prakash V . CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8 T cell antitumor immunity. Immunity. 2023; 56(7):1613-1630.e5. PMC: 10752240. DOI: 10.1016/j.immuni.2023.06.003. View

19.

Patel S, Karlitz J, Yen T, Lieu C, Boland C . The rising tide of early-onset colorectal cancer: a comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early detection. Lancet Gastroenterol Hepatol. 2022; 7(3):262-274. DOI: 10.1016/S2468-1253(21)00426-X. View

20.

Zhao Q, Zhang R, Qiao C, Miao Y, Yuan Y, Zheng H . Ubiquitination network in the type I IFN-induced antiviral signaling pathway. Eur J Immunol. 2023; 53(9):e2350384. DOI: 10.1002/eji.202350384. View